• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Owens & Minor Inc.

    4/6/23 4:50:15 PM ET
    $OMI
    Medical Specialities
    Health Care
    Get the next $OMI alert in real time by email
    SC 13G 1 e618481_sc13g-om.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (Amendment No. ) *

     

    Owens & Minor, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    690732102

    (CUSIP Number)

     

    March 31, 2023 

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    (Page 1 of 9 Pages)

     

    ----------

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

          

    CUSIP No. 690732102 13G Page 2 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Mgmt, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    4,202,667 (1)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    4,202,667 (1)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,202,667 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.51%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

    __________________

    (1) Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

        

    CUSIP No. 690732102 13G Page 3 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Management Company, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    4,202,667 (2)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    4,202,667 (2)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,202,667 (2)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.51%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

    __________________

    (2) Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Management Company, L.P. is the investment advisor.

         

    CUSIP No. 690732102 13G Page 4 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Partners, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    4,202,667

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    4,202,667

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,202,667

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.51%

    12.

    TYPE OF REPORTING PERSON*

     

    PN 

      

    CUSIP No. 690732102 13G Page 5 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    James E. Flynn

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    4,202,667 (3)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    4,202,667 (3)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,202,667 (3)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.51%

    12.

    TYPE OF REPORTING PERSON*

     

    IN

    __________________

    (3) Comprised of shares of common stock held by Deerfield Partners, L.P.

         

    CUSIP No. 690732102 13G Page 6 of 9

     

    Item 1(a). Name of Issuer:
       
     

    Owens & Minor, Inc.

       
    Item 1(b). Address of Issuer's Principal Executive Offices:
       
     

    9120 Lockwood Boulevard

    Mechanicsville, VA, 23116

       
    Item 2(a). Name of Person Filing:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P.

       
    Item 2(b). Address of Principal Business Office, or if None, Residence:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010

       
    Item 2(c). Citizenship:
       
     

    Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships;

     

    James E. Flynn – United States citizen

       
    Item 2(d). Title of Class of Securities:
       
     

    Common Stock

       
    Item 2(e). CUSIP Number:
       
     

    690732102

         
    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

       
    (a) ☐

    Broker or dealer registered under Section 15 of the Exchange Act.

         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) ☐

    Insurance company as defined in Section 3(a)(19) of the Exchange Act.

         
    (d) ☐

    Investment company registered under Section 8 of the Investment Company Act.

         
    (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ☐

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

         
    (g) ☐

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

         

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

         
    (i) ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    CUSIP No. 690732102 13G Page 7 of 9

     

         
    (j) ☐ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

     

    Item 4. Ownership.
           

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

           
    (a) Amount beneficially owned**:  
           
     

    Deerfield Mgmt, L.P. - 4,202,667 shares

    Deerfield Management Company, L.P. - 4,202,667 shares

    Deerfield Partners, L.P. - 4,202,667 shares

    James E. Flynn – 4,202,667 shares

           
    (b) Percent of class**:  
           
     

    Deerfield Mgmt, L.P. – 5.51%

    Deerfield Management Company, L.P. – 5.51%

    Deerfield Partners, L.P. – 5.51%

    James E. Flynn – 5.51%

           
    (c) Number of shares as to which such person has**:  
           
      (i) Sole power to vote or to direct the vote: All Reporting Persons - 0
           
      (ii) Shared power to vote or to direct the vote:

    Deerfield Mgmt, L.P. - 4,202,667

    Deerfield Management Company, L.P. - 4,202,667

    Deerfield Partners, L.P. - 4,202,667

    James E. Flynn – 4,202,667

           
      (iii)

    Sole power to dispose or to direct the disposition of:

    All Reporting Persons - 0
           
      (iv)

    Shared power to dispose or to direct the disposition of:

    Deerfield Mgmt, L.P. - 4,202,667

    Deerfield Management Company, L.P. - 4,202,667

    Deerfield Partners, L.P. - 4,202,667

    James E. Flynn – 4,202,667

      

    **See footnotes on cover pages which are incorporated by reference herein.

     

    CUSIP No. 690732102 13G Page 8 of 9

     

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following ☐.

       
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

       

    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       

    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      See Exhibit B
       
    Item 9. Notice of Dissolution of Group.
       

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A
       
    Item 10. Certifications.
       

    "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

     

    CUSIP No. 690732102 13G Page 9 of 9

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    DEERFIELD MGMT, L.P. 

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

          Jonathan Isler, Attorney-In-Fact

     

     

    DEERFIELD MANAGEMENT COMPANY, L.P. 

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

          Jonathan Isler, Attorney-In-Fact

     

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

          Jonathan Isler, Attorney-In-Fact

     

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    Date: April 6, 2023

     

     

     

     

    Exhibit List

     

    Exhibit A. Joint Filing Agreement.

     

    Exhibit B. Item 8 Statement.

     

    Exhibit C. Power of Attorney (1).

     

    (1) Power of Attorney previously filed as Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.

     

     

     

     

    Exhibit A

     

    Joint Filing Agreement

     

    The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Owens & Minor, Inc. shall be filed on behalf of the undersigned.

     

     

    DEERFIELD MGMT, L.P. 

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

          Jonathan Isler, Attorney-In-Fact

     

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

          Jonathan Isler, Attorney-In-Fact

     

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

          Jonathan Isler, Attorney-In-Fact

     

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

     

     

     

    Exhibit B

     

    Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

     

     

    Get the next $OMI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMI

    DatePrice TargetRatingAnalyst
    7/19/2024$24.00 → $19.00Neutral → Buy
    Citigroup
    2/26/2024$24.00Market Perform
    Leerink Partners
    1/3/2024$21.00Equal Weight
    Barclays
    10/13/2022$52.00 → $18.00Buy → Neutral
    Citigroup
    10/12/2022$43.00 → $17.00Buy → Underperform
    BofA Securities
    10/12/2022$62.00 → $22.00Outperform → Neutral
    Robert W. Baird
    4/26/2022$55.00Buy
    Citigroup
    4/1/2022$43.00Neutral
    Credit Suisse
    More analyst ratings

    $OMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Coliseum Capital Management, Llc bought $3,073,750 worth of shares (410,000 units at $7.50) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      4/10/25 9:43:55 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Large owner Coliseum Capital Management, Llc bought $4,291,218 worth of shares (528,356 units at $8.12) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      4/7/25 8:21:15 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Large owner Coliseum Capital Management, Llc bought $27,386,158 worth of shares (2,893,412 units at $9.47) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      3/4/25 9:07:16 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Owens & Minor upgraded by Citigroup with a new price target

      Citigroup upgraded Owens & Minor from Neutral to Buy and set a new price target of $19.00 from $24.00 previously

      7/19/24 7:41:01 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Leerink Partners initiated coverage on Owens & Minor with a new price target

      Leerink Partners initiated coverage of Owens & Minor with a rating of Market Perform and set a new price target of $24.00

      2/26/24 8:10:20 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Owens & Minor with a new price target

      Barclays initiated coverage of Owens & Minor with a rating of Equal Weight and set a new price target of $21.00

      1/3/24 8:05:34 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Owens & Minor Reports First Quarter 2025 Financial Results

      Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e

      5/8/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces First Quarter 2025 Earnings Release Date and Conference Call

      Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b

      5/1/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces Major Innovations to Products & Healthcare Services Network

      Transformative investments in technology, automation and analytics capabilities will help improve supply chain visibility and resiliency for Products & Healthcare Services customers and lay the foundation for future innovations Owens & Minor, Inc. (NYSE:OMI) today announced important milestones in advancing the medical distribution capabilities of its Products & Healthcare Services (P&HS) business segment, which provides essential products and services to thousands of healthcare customers. These milestones are the result of recent company investments in new technology, automation and analytics capabilities geared specifically toward driving greater efficiencies for the P&HS segment and imp

      4/9/25 4:30:00 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Owens & Minor Inc.

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      11/12/24 10:32:12 AM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      2/13/24 5:12:07 PM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      2/12/24 5:29:41 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Financials

    Live finance-specific insights

    See more

    $OMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $OMI
    SEC Filings

    See more

    $OMI
    Leadership Updates

    Live Leadership Updates

    See more
    • Owens & Minor Reports First Quarter 2025 Financial Results

      Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e

      5/8/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces First Quarter 2025 Earnings Release Date and Conference Call

      Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b

      5/1/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Reports Fourth Quarter & Full Year Financial Results and Announces Sale Process Underway for Products & Healthcare Services Segment

      Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million 2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment Board of Directors Authorizes Share Repurchase Program of Up to $100 Million Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the fourth quarter and year ended December 31, 2024. "We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Prod

      2/28/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Director Rollins Carissa was granted 28,914 shares, increasing direct ownership by 116% to 53,902 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/16/25 6:11:21 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Director Kline Teresa L. was granted 28,914 shares, increasing direct ownership by 115% to 54,125 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/16/25 6:10:49 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Director Henkel Robert J was granted 28,914 shares, increasing direct ownership by 60% to 77,412 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/16/25 6:10:08 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      5/16/25 8:30:34 AM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Owens & Minor Inc.

      10-Q - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      5/8/25 4:05:35 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      5/8/25 6:35:09 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Names Tammy Gomez EVP and Chief Human Resources Officer

      Gomez assumes leadership of Owens & Minor's people strategy with a focus on cultivating talent that supports company performance Owens & Minor, Inc. (NYSE:OMI), a leading global healthcare solutions company, today announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11, 2022. Gomez will report to Owens & Minor's President and Chief Executive Officer, Edward A. Pesicka, and be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005306/en/Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer, effect

      6/22/22 6:50:00 AM ET
      $OMI
      Medical Specialities
      Health Care